A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Single- and Multiple-Ascending Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB095 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 17 May 2019
Price : $35 *
At a glance
- Drugs BIIB-095 (Primary)
- Indications Neuropathic pain
- Focus Adverse reactions
- Sponsors Biogen
- 15 May 2019 Status changed from recruiting to completed.
- 28 Feb 2019 Planned End Date changed from 28 Jan 2019 to 17 Apr 2019.
- 28 Feb 2019 Planned primary completion date changed from 28 Jan 2019 to 17 Apr 2019.